Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.59 |
| ▸ | HTR2A | P28223 | 6/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988223 | 0.90 | TAAR1 (0.53) | TAAR1HTR2AHTR2CKDM4E | |
| SCHEMBL29528198 | 0.86 | HTR2A (0.68) | TAAR1HTR2AHTR2CCYP1A2 | |
| SCHEMBL1067850 | 0.86 | HTR2A (0.68) | TAAR1HTR2AHTR2CCYP1A2 | |
| Hydrochloric Acid SCHEMBL29386152 | 0.85 | HTR2A (0.66) | TAAR1HTR2AHTR2CCYP1A2 | |
| Hydrochloric Acid SCHEMBL22614745 | 0.85 | HTR2A (0.66) | TAAR1HTR2AHTR2CCYP1A2 | |
| SCHEMBL1253319 | 0.81 | TAAR1 (0.77) | TAAR1HTR2AHTR2CADRA1A | |
| SCHEMBL29364056 | 0.81 | TAAR1 (0.77) | TAAR1HTR2AHTR2CADRA1A | |
| SCHEMBL21240834 | 0.81 | TAAR1 (0.83) | TAAR1HTR2AHTR2CADRA1A | |
| SCHEMBL25143222 | 0.80 | MTNR1A (0.45) | TAAR1HTR2AHTR2CCYP1A2 | |
| SCHEMBL244435 | 0.80 | HTR2A (0.76) | TAAR1HTR2AHTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014066772-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-0789577-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-5877278-A | SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS | CHIRON CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0789577-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0789577-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | ABL1, ARSA, AADAC | TAAR1 535/4885HTR2A 3860/4885HTR2C 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.